CD7‐targeting pro‐apoptotic extracellular vesicles: A novel approach for T‐cell haematological malignancy therapy
Journal of Extracellular Vesicles · 2024
DOI: 10.1002/jev2.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2024. Verfasst von Bei Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics of the Second Affiliated Hospital and Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Apoptosis, Antigens, CD7. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Preresearch Fund for Clinical Scientific Research of Hangzhou First People's Hospital Affiliated to Zhejiang University, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
T‐cell haematological malignancies progress rapidly and have a high mortality rate and effective treatments are still lacking. Here, we developed a drug delivery system utilizing 293T cell‐derived extracellular vesicles (EVs) modified with an anti‐CD7 single‐chain variable fragment (αCD7/EVs). Given the challenges of chemotherapy resistance in patients with T‐cell malignancy, we selected cytochrome C (CytC) and Bcl2 siRNA ( siBcl2 ) as therapeutic agents and loaded them into αCD7/EVs (αCD7/EVs/CytC/ siBcl2 ). We found that αCD7/EVs efficiently targeted and were internalized by human T‐ALL Molt‐4 cells. In addition, the interaction between αCD7 and CD7 switched the EV entry pathway in Molt‐4 cells from macropinocytosis‐dependent endocytosis to clathrin‐mediated endocytosis, thereby reducing EV‐lysosome colocalization, ultimately improving CytC delivery efficiency and increasing the cytotoxicity of nascent EVs from EV‐treated Molt‐4 cells. Notably, αCD7/EVs/CytC/ siBcl2 demonstrated similar efficacy against both Molt‐4 and chemotherapy‐resistant Molt‐4 cells (CR‐Molt‐4). Furthermore, αCD7/EVs/CytC/ siBcl2 exhibited high safety, low immunogenicity and minimal impact on human T cells. Therefore, αCD7/EVs/CytC/ siBcl2 are promising therapeutic approaches for treating CD7 + T‐cell malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics of the Second Affiliated Hospital and Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Key Laboratory of Functional and Clinical Translational Medicine, Fujian province university, Xiamen Medical College, Xiamen, China.
- Institute of Respiratory Diseases Xiamen Medical College, Xiamen, China.
- Organiod platform of medical laboratory science, Xiamen medical college, Xiamen, China.
- Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
ORCID-Profile: Bei Zhang, Jiaoli Wang, Zhijian Cai
Förderung
- Joint Preresearch Fund for Clinical Scientific Research of Hangzhou First People's Hospital Affiliated to Zhejiang University
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Major Project of Hangzhou Health Science and Technologyn Plan
- the Natural Science Foundation of Fujian Province, China
- Natural Science Foundation of Xiamen, China
- the Project of Xiamen Medical College, China
Zitieren
APA
Zhang, B., Chen, J., Chen, J., Shen, Y., Chen, Y., Wang, S., Zhang, C., He, Y., Feng, H., Wang, J., & Cai, Z. (2024). CD7‐targeting pro‐apoptotic extracellular vesicles: A novel approach for T‐cell haematological malignancy therapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70025
Vancouver
Zhang B, Chen J, Chen J, Shen Y, Chen Y, Wang S, et al. CD7‐targeting pro‐apoptotic extracellular vesicles: A novel approach for T‐cell haematological malignancy therapy. Journal of Extracellular Vesicles. 2024. doi:10.1002/jev2.70025
BibTeX
@article{Zhang2024,
author = {Zhang, Bei and Chen, Jianqiang and Chen, Jiming and Shen, Yingying and Chen, Yinghu and Wang, Shibo and Zhang, Chengyan and He, Yuzhou and Feng, Huajun and Wang, Jiaoli and Cai, Zhijian},
title = {CD7‐targeting pro‐apoptotic extracellular vesicles: A novel approach for T‐cell haematological malignancy therapy},
journal = {Journal of Extracellular Vesicles},
year = {2024},
doi = {10.1002/jev2.70025}
}
EUVIMED